Navigation Links
Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
Date:9/17/2007

First internal candidate to enter Phase 2 clinical development

PRINCETON, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the initiation of a Phase 2a clinical study of PS433540, the company's lead internal product candidate. PS433540 is a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically proven mechanisms of action in a single compound. The compound works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Preclinical studies have shown that PS433540 is highly selective for the AII receptor sub-type 1 and the ET receptor sub-type A. As such PS433540 combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule. There are considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

The objective of the Phase 2a randomized, double-blind, placebo- controlled, parallel-group study is to evaluate the compound's safety and efficacy in subjects with Stage I and Stage II hypertension. This multi- center trial is expected to enroll 170 subjects. After a lead-in period, patients will be randomized into three study arms (placebo and two active arms
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 Pharmaceutical and biotech marketers ... products for the same indication. This can be a ... to prevent one of their brands from gaining market ... to recent research by benchmarking firm, Best Practices, LLC, ... brands rather than together as part of a franchise. ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9
(Date:3/1/2015)... 2015 Researchers say working around asbestos-containing ... sheet metal workers contract malignant mesothelioma. Surviving Mesothelioma has ... its website. Click here to read it now. ... and Training monitored 17,345 sheet metal workers from 1986 ... them died of mesothelioma or another asbestos-related disease ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 ERISAPros ... King and Carolyn Roddy to the professional staff of ... Compliance, graduated from The Ohio State University-Mortiz College of ... years of experience working with several Fortune 500 companies ... the area of corporate benefits. Her experiences range from ...
(Date:2/28/2015)... In recent years Medical Marijuana has continuously ... as a way for them to expand their patient base ... medicine. Since the FDA still lists Cannabis as a Schedule ... licensed physicians that can help guide them when recommending ... in Santa Cruz, CA is a leader in the ...
(Date:2/28/2015)... 2015 The Heart Fit Clinic started ... of the machine. The Heart Fit Clinic is also ... a franchise model. The goal is to scale the ... disease. To buy External Counterpulsation machines can ... individuals through this process and achieve the desired results. ...
(Date:2/28/2015)... Indosoft Inc , developers of ... are pleased to announce the development of Q-Suite 5.9. ... versions of Q-Suite, this new version will include enhancements ... new features to the leading edge call center software. ... will add features to enhance security and protection. Administrators ...
Breaking Medicine News(10 mins):Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2
... immune system, says a study conducted by Spanish researchers . ... C, B-complex vitamins and has good doses of minerals like ... known that potatoes are good for bowel health. ... particularly if eaten cold or in a salad, the researchers ...
... to the coastal Spanish town of Altea to get Oslo-funded ... to fractured bones. ,"In Norway it is cold ... why they are better off here," the tanned head of ... ,The rehabilitation centre was set up and is run by ...
... are an indicator of an industry's health, then the turnout ... and spirits fair, confirms the sector is doing nicely, if ... this year's show, a two-yearly event in Bordeaux, a three ... for Vinexpo by the London-based International Wine and Spirit Record ...
... with a life-threatening illness, a young Indian American is hard ... 10 as very few South Asians are listed in the ... Chakravarthy was diagnosed with a disease known as Acute Myelogenous ... bone marrow, the South Asian community has come together nationwide ...
... up with a partner in Harley Street - a ... are frequented by celebrities - and is introducing ... into tie-up based on her franchise system with the ... Ayurveda on Harley Street is indicative of the increasing ...
... Fey has launched an entirely new kind of healthcare ... culture of prevention throughout America and the world -- ... to one that encourages people to take early steps ... ,This message appears this week in a full-page ad in ...
Cached Medicine News:Health News:Intake of Potatoes Boosts the Immune System 2Health News:Norwegians Take in the Sun in Spain on Doctors' Orders 2Health News:World Wine Sales Brisk, but French Producers Hungover 2Health News:World Wine Sales Brisk, but French Producers Hungover 3Health News:South Asians Seek Bone Marrow for Young Indian American 2Health News:Shahnaz Hussain Takes Ayurveda to London's Harley Street 2Health News:U.S. Preventive Medicine(R) Encourages the International Community to Embrace Prevention 2
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide smooth handle with polished finish....
Smooth 90 degree jaws with locking screw maintain proper stretch of sleeve for securing silicone bands....
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 ga. shaft tapering to 23 ga., 10 mm from tip. Overall length from rear rotation knob to tip....
Medicine Products: